Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
Zynerba Pharmaceuticals, Inc. (ZYNE)
Last zynerba pharmaceuticals, inc. earnings: 3/10 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.zynerba.com
Company Research
Source: GlobeNewswire
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 - Presentation Today at the 57th Annual Meeting of the American College of Neuropsychopharmacology - DEVON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders,
Show less
Read more
Impact Snapshot
Event Time:
ZYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYNE alerts
High impacting Zynerba Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ZYNE
News
- Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswire
- Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational HighlightsGlobeNewswire
- Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual MeetingGlobeNewswire
- Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual MeetingGlobeNewswire
- Zynerba Pharmaceuticals, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ZYNE/price-target/">NASDAQ: ZYNE</a>) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.MarketBeat
ZYNE
Earnings
- 5/16/22 - Beat
ZYNE
Sec Filings
- 5/16/22 - Form S-3
- 5/16/22 - Form 10-Q
- 5/16/22 - Form 8-K
- ZYNE's page on the SEC website